Skip to main content

Table 3 Univariate and multivariate analysis of factors affecting the development of hepatotoxicity with erlotinib

From: Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study

Variable

Univariate analysis

P

Multivariate analysis

 
 

No. of patients (%) a

 

OR (95% CI)

Pf

 

Absence

Presence

   
 

(n = 69)

(n = 26)

   

Age (years)

 Median [range]

68 [37–87]

68 [55–83]

0.565 d

  

 <  75

57 (83)

21 (81)

1.000 e

  

 ≥ 75

12 (17)

5 (19)

   

Sex

 Male

40 (58)

10 (39)

0.109 e

2.032 (0.787–5.248)

0.143

 Female

29 (42)

16 (62)

   

ECOG PS

 0–1

60 (87)

24 (92)

0.722 e

  

 2–3

9 (13)

2 (8.0)

   

Stage

 I-III

26 (38)

10 (39)

1.000 e

  

 IV

43 (62)

16 (62)

   

BSA (m2)

 Median [range]

1.6 [1.1–2.0]

1.6 [1.3–1.9]

0.478 d

  

 <  1.6

39 (57)

15 (58)

1.000 e

  

 ≥ 1.6

30 (43)

11 (42)

   

BMI (kg/m2)

 Median [range]

22.1 [15.3–30.3]

21.4 [16.8–29.1]

0.652 d

  

 < BMI 25

59 (86)

22 (85)

1.000 e

  

 ≥ BMI 25

10 (15)

4 (15)

   

Recurrence

 Yes

23 (33)

11 (42)

0.475 e

  

 No

46 (67)

15 (58)

   

Metastasis

 Yes

64 (93)

24 (92)

1.000 e

  

 No

5 (7)

2 (8.0)

   

Line of therapy

 First line

18 (26)

8 (31)

0.797 e

  

 Second line and later line

51 (74)

18 (69)

   

EGFR mutation

 Exon 19 Deletion

  Yes

24 (35)

10 (39)

0.812 e

  

  No

45 (65)

16 (62)

   

 Exon 21 L858R point mutation

  Yes

27 (39)

11 (42)

0.817 e

  

  No

42 (60)

15 (58)

   

Smoking history

 Yes

36 (52)

10 (39)

0.258 e

  

 No

33 (48)

16 (62)

   

Grade 1 liver dysfunction b

 Yes

21 (30)

10 (38)

0.471 e

  

 No

48 (70)

16 (62)

   

Concomitant medication c

 AS

     

  Yes

40 (58)

8 (31)

0.022 e

0.341 (0.129–0.900)

0.030

  No

29 (42)

18 (69)

   

CYP1A2 inducer

 Yes

2 (3.0)

0 (0.0)

1.000 e

  

 No

67 (97)

26 (100)

   

CYP3A4 inducer

 Yes

2 (3.0)

0 (0.0)

1.000 e

  

 No

67 (97)

26 (100)

   

CYP3A4 inhibitor

 Yes

5 (7.0)

1 (4.0)

1.000 e

  

 No

64 (93)

25 (96)

   
  1. a The sum of the percentages may not equal 100% because of rounding off
  2. b Any of AST, ALT, T-Bil, or ALP grade 1 as evaluated by CTCAE version 5.0 at the start of treatment
  3. c Concomitant medications that were being taken at the time of the hepatotoxicity
  4. d Mann-Whitney U test
  5. e Fisher’s exact test
  6. f Logistic regression analysis
  7. OR odds ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, BSA body Surface Area, BMI body mass index, EGFR epidermal growth factor receptor, AS acid-suppressing medications, CYP cytochrome P450